Skipping day 2 antiemetic medications may improve chemotherapy induced delayed nausea and vomiting control: Results of two pilot phase II trials

Supportive Care in Cancer

Volumn 15, Issue 3, 2007, Pages 343-346

  Lajolo, Paula P ^a,b   Del Giglio, Auro ^a  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antiemetics; Antineoplastic combined chemotherapy protocols; Chemically induced vomiting; Economics; Granisetron administration and dosage; Prevention and control of vomiting; Tachyphylaxis; Vomiting

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; GRANISETRON; METOCLOPRAMIDE; ONDANSETRON;

ADULT; AGED; APPETITE; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE CONTROL; DIZZINES; DIZZINESS; DRUG USE; DRY EYE; EDEMA; EPIGASTRIC PAIN; FEMALE; FEVER; HEADACHE; HUMAN; INSOMNIA; LOGISTIC REGRESSION ANALYSIS; MALE; MYALGIA; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; URINE VOLUME; WEAKNESS; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAZIL; DEXAMETHASONE; DRUG HYPERSENSITIVITY; FEMALE; GRANISETRON; HUMANS; HYPERSENSITIVITY, DELAYED; LOGISTIC MODELS; MALE; METOCLOPRAMIDE; MIDDLE AGED; NAUSEA; ONDANSETRON; PILOT PROJECTS; QUALITY OF LIFE; RESEARCH DESIGN; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME; VOMITING;

EID: 33847102265     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-006-0134-6     Document Type: Article

References (11)

1. The Italian Group or Antiemetic Research (2000) Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342:1554-1559
2. Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S et al (2005) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 13:85-96
3. Fox SM, Einhorn LH, Cox E, Powell N, Abdy A (1993) Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 11:2391-2395
4. Sjoqvist A, Cassuto J, Jodal M, Lundgren O (1992) Actions of serotonin antagonists on cholera-toxin-induced intestinal fluid secretion. Acta Physiol Scand 145:229-237
5. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-4119
6. Gralla RJ, de Wit R, Herrstedt J, Carides AD, Ianus J, Guoguang-Ma J et al (2005) Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer 104:864-868
7. Moreno J, Sahade M, del Giglio A (2005) Low-dose granisetron for prophylaxis of acute chemotherapy-induced nausea and vomiting: a pilot study. Support Care Cancer 13:850-853
8. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971-2994
9. Mullin SM, Fletcher DM, Tyler LS (1998) Mail-in questionnaire for monitoring nausea and vomiting in oncology outpatients. Am J Health Syst Pharm 55:1903-1906
10. Decker GM, DeMeyer ES, Kisko DL (2006) Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 4:35-41, 52
11. Martin AR, Pearson JD, Cai B et al (2000) Validation of a 5-day recall version of the Functional Living Index-Emesis (FLIE) quality of life questionnaire for chemotherapy-induced emesis. Qual Life Res 9:18